Harrow Launches "Harrow Cares" Program in Partnership with Cencora

Harrow, a leading eye care pharmaceutical company in North America, has announced the launch of Harrow Cares, a new initiative developed in collaboration with Cencora, a global leader in pharmaceutical solutions. This program aims to enhance access and affordability services for retina specialists, their staff, and patients, ensuring greater support in ophthalmic care.

Strengthening Patient Support and Access to Treatment

The Harrow Cares program includes a comprehensive patient support services hub designed to:

       • Streamline enrollment processes

       • Facilitate quick access to therapies

       • Provide personalized support for both providers and patients

By offering these services, the program will enable retina specialists to confidently integrate IHEEZO and TRIESENCE into their clinical practices, ensuring smoother treatment experiences.

A Shared Commitment to Accessibility and Affordability

Mark L. Baum, Chief Executive Officer of Harrow, emphasized the importance of the partnership with Cencora in addressing critical challenges in healthcare:

“We are thrilled to collaborate with Cencora on the launch of our ‘Harrow Cares’ program. This partnership reflects our shared commitment to addressing one of the most critical challenges in healthcare – ensuring that life-changing medications are both accessible and affordable. The Harrow Cares initiative underscores Harrow’s unwavering dedication to creating meaningful solutions that empower patients, reduce barriers to treatment, and drive better health outcomes.”

Key Program Features and Benefits

In addition to patient support services, Harrow Cares will offer:

       • Real-time benefit verifications for seamless insurance and payment processing

       • Flexible affordability options to improve financial access to medications

       • Product assurance programs for enhanced treatment reliability

Expanding Harrow’s Presence in the Retina Market

Baum highlighted how this initiative aligns with Harrow’s strategic growth objectives in the U.S. retina market:

“This milestone highlights our strategic focus on expanding and solidifying Harrow’s presence in the U.S. retina market, a key area of growth and innovation for our company. We look forward to working closely with Cencora to advance innovative ophthalmic solutions that enhance patient care and improve access to vital treatments.”

Conclusion

The launch of Harrow Cares represents a significant step in enhancing access, affordability, and support services for retina specialists and their patients. Through its collaboration with Cencora, Harrow is reinforcing its commitment to improving patient care, reducing barriers to treatment, and driving innovation in ophthalmology.